🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Edith A. Perez

Jacksonville College

ORCID: 0000-0002-5037-6677

Also affiliated with WinnMed, Mayo Clinic in Arizona, Mayo Clinic in Florida

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 13 papers. Top paper: “Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States”.

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Value in Health(2019)10.1016/j.jval.2018.11.014
N/A
0.581DataRank · unranked
47 citations

Joseph Babigumira, Clément Tournier, Hans-Peter Goertz, Solomon J. Lubinga, Edith A. Perez +1 more

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

npj Breast Cancer(2022)10.1038/s41523-022-00430-0
N/A
0.417DataRank · unranked
8 citations

Zhuo Li, Daniel Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner +20 more

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial

Clinical Breast Cancer(2021)10.1016/j.clbc.2021.11.012
N/A
0.413DataRank · unranked
10 citations

Yaohua Ma, Claudia De Angelis, François Richard, Christine Desmedt, Ahmad Awada +7 more

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07417-4
N/A
0.215DataRank · unranked
3 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2024.7015
N/A
0.104DataRank · unranked
1 citations

Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil, Alvaro Moreno‐Aspitia +7 more

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Digital Commons@Becker (Washington University School of Medicine)(2020)10.17615/6e7v-pv95
N/A
0DataRank · unranked
1 citations

Tracy Lively, John A. Olson, Robert J. Gray, Virginia Kaklamani, Della Makower +26 more

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer

Nature Communications(2023)10.1038/s41467-023-37806-0
N/A
0DataRank · unranked
44 citations

Saranya Chumsri, Douglas Hinerfeld, Yaohua Ma, Xue Wang, David Zahrieh +21 more

Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival

JAMA Network Open(2023)10.1001/jamanetworkopen.2023.39584
N/A
0DataRank · unranked
17 citations

Karla V. Ballman, Jordan D. Campbell, Hyman B. Muss, Edith A. Perez, Lawrence N. Shulman +4 more

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Research Square(2024)10.21203/rs.3.rs-4295044/v1
N/A
0DataRank · unranked
0 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.529
N/A
0DataRank · unranked
0 citations

Angelica Gil, Yaohua Ma, Zhuo Li, Pooja Advani, Alvaro Moreno‐Aspitia +5 more

Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.510
N/A
0DataRank · unranked
2 citations

Jodi M. Carter, Yaohua Ma, Douglas Hinerfeld, Heather Ann Brauer, Sarah Warren +15 more

miR-221-5p-Mediated Downregulation of JNK2 Aggravates Acute Lung Injury

Frontiers in Immunology(2021)10.3389/fimmu.2021.700933
N/A
0DataRank · unranked
21 citations

Hanh Chi Do-Umehara, Qiao Zhang, Huashan Wang, Changchun Hou, Huali Dong +9 more

Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1

Frontiers in Immunology(2021)10.3389/fimmu.2021.648815
N/A
0DataRank · unranked
6 citations

Edith A. Perez, Changchun Hou, Pin Zhang, Michelle Van Scoyk, Robert A. Winn +3 more